United States

Biospecifics Technologies Corp (BSTC.OQ)

BSTC.OQ on NASDAQ Stock Exchange Global Market

1:10pm EDT
Change (% chg)

$0.03 (+0.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Biospecifics Technologies Q4 earnings per share $0.40
Wednesday, 15 Mar 2017 08:00am EDT 

Biospecifics Technologies Corp : Biospecifics Technologies Corp reports fourth quarter and full year 2016 financial results . Q4 earnings per share $0.40 .Biospecifics Technologies Corp says total revenue for q4 ended december 31, 2016 was $6.6 million, compared to $6.1 million for same period in 2015.  Full Article

Biospecifics Q2 earnings per share $0.35
Tuesday, 9 Aug 2016 04:05pm EDT 

Biospecifics Technologies Corp : Q2 earnings per share $0.35 . Biospecifics technologies corp. Reports second quarter 2016 financial results .Q2 revenue rose 32 percent to $6.2 million.  Full Article

Biospecifics Technologies positive results from phase 2 trial of CCH
Monday, 13 Jun 2016 07:30am EDT 

Biospecifics Technologies Corp : Biospecifics technologies corp. Announces positive top-line results from phase 2 trial of cch for treatment of human lipoma . Trial met its primary endpoint of reduction in visible surface area of target lipomas relative to placebo . There were no serious adverse events reported during trial .Announces Positive Top-Line results from phase 2 trial of cch for treatment of human lipoma.  Full Article

BioSpecifics Technologies Q1 earnings per share $0.39
Tuesday, 10 May 2016 07:53am EDT 

Biospecifics Technologies Corp : Total revenue for Q1 ended march 31, 2016 was $6.6 million , compared to $5.6 million for same period in 2015 . BioSpecifics Technologies Corp says co expects to initiate a clinical trial of CCH in uterine fibroids in second half of 2016 . Line results for its trial of cch in human lipoma in june of 2016 . BioSpecifics Technologies Corp. Reports first quarter 2016 financial results .Q1 earnings per share $0.39.  Full Article

BioSpecifics Technologies Corp announces approval of XIAFLEX in Japan for treatment of Dupuytren's Contracture
Monday, 20 Jul 2015 08:00am EDT 

BioSpecifics Technologies Corp:Says that Asahi Kasei Pharma Corp (Asahi Kasei) has received approval for its regulatory application to Japanese Pharmaceutical and Medical Device Agency for XIAFLEX(collagenase clostridium histolyticum) for treatment of patients with Dupuytren's contracture in Japan.Asahi has rights to develop and market XIAFLEX in Japan through an agreement with BioSpecifics' partner Endo International plc (Endo).BioSpecifics will receive a milestone payment upon commercial launch in Japan.  Full Article

More From Around the Web

BRIEF-Biospecifics Technologies announces positive data from mid-stage study in patients with cellulite

* CCH was well-tolerated in actively treated subjects with most adverse events being mild to moderate in severity